CPI-1189 is primarily investigated for its potential neuroprotective properties, particularly in the context of neurodegenerative diseases. It has shown activity in reducing neuronal cell death by modulating key inflammatory pathways in the brain. The compound inhibits the production of pro-inflammatory cytokines and suppresses inducible nitric oxide synthase (iNOS), which plays a role in oxidative stress and neuroinflammation. Due to these effects, CPI-1189 has been studied as a candidate therapeutic agent in conditions such as Alzheimer's disease and other disorders involving chronic inflammation and neuronal damage. Its ability to cross the blood-brain barrier enhances its potential for central nervous system applications. Research remains largely in preclinical stages, with focus on understanding optimal dosing and long-term effects.